Xconomy | Boston - Business + Technology in the Exponential Economy

Deal, Life Sciences, cancer

Forma, Novartis Strike Drug Deal

Ryan McBride 1/12/09

Forma Therapeutics, a Cambridge, MA-based developer of cancer drugs, reports it has struck a license and option agreement with Swiss drug giant Novartis, through Forma investor Novartis Option Fund. Novartis will pay Forma an upfront fee and potential payments of more than $200 million, providing Novartis the option to license from Forma drugs that inhibit an undisclosed protein-protein interaction in the field of oncology. (I wrote last week that Forma was expecting to announce this deal.)

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.